Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Biomaterials ; 120: 115-125, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28056401

RESUMO

Magnetic hyperthermia as a treatment modality is acquiring increased recognition for loco-regional therapy of primary and metastatic lung malignancies by pulmonary delivery of magnetic nanoparticles (MNP). The unique characteristic of magnetic nanoparticles to induce localized hyperthermia in the presence of an alternating magnetic field (AMF) allows for preferential killing of cells at the tumor site. In this study we demonstrate the effect of hyperthermia induced by low and high dose of MNP under the influence of an AMF using 3D tumor tissue analogs (TTA) representing the micrometastatic, perfusion independent stage of triple negative breast cancer (TNBC) that infiltrates the lungs. While application of inhalable magnetic nanocomposite microparticles or magnetic nanocomposites (MnMs) to the micrometastatic TNBC model comprised of TTA generated from cancer and stromal cells, showed no measureable adverse effects in the absence of AMF-exposure, magnetic hyperthermia generated under the influence of an AMF in TTA incubated in a high concentration of MNP (1 mg/mL) caused significant increase in cellular death/damage with mechanical disintegration and release of cell debris indicating the potential of these inhalable composites as a promising approach for thermal treatment of diseased lungs. The novelty and significance of this study lies in the development of methods to evaluate in vitro the application of inhalable composites containing MNPs in thermal therapy using a physiologically relevant metastatic TNBC model representative of the microenvironmental characteristics in secondary lung malignancies.


Assuntos
Hipertermia Induzida/métodos , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/terapia , Magnetoterapia/métodos , Nanopartículas de Magnetita/uso terapêutico , Neoplasias de Mama Triplo Negativas/patologia , Animais , Linhagem Celular Tumoral , Sobrevivência Celular , Neoplasias Pulmonares/patologia , Camundongos , Micrometástase de Neoplasia/patologia , Micrometástase de Neoplasia/terapia , Resultado do Tratamento , Neoplasias de Mama Triplo Negativas/terapia
2.
Epilepsy Behav ; 14(2): 300-8, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19100339

RESUMO

The purpose of the study was to investigate whether dietary intake of curcumin can inhibit the onset and progression of seizures and their associated pathophysiology in experimental FeCl(3)-induced epileptogenesis. Curcumin was considered for this study because it can cross the blood-brain barrier and bind redox-active metal ions. It is also well known for its antioxidative, anticancer, and anti-inflammatory properties. In the present study, seizures were induced by intracortical injection of FeCl(3) into young rats. Synchronized video/EEG recordings were obtained to diagnose the progression of seizures. Short-term treatment with a curcumin-supplemented diet (1500 pp mw/w) significantly inhibited the onset of grade III and IV seizures in rats with iron-induced epilepsy. The lower dose of curcumin (500 ppm) was not effective in inhibiting grade III seizures, but retarded the onset and progression of generalized seizures. The seizure-suppressing potential of curcumin is explained by the observed biochemical, behavioral, and ultrastructural results. Our results indicate that curcumin significantly prevents generalization of electroclinical seizure activity as well as the pathogenesis associated with iron-induced epileptogenesis.


Assuntos
Antioxidantes/uso terapêutico , Curcumina/uso terapêutico , Epilepsia/induzido quimicamente , Epilepsia/prevenção & controle , Compostos Férricos , Animais , Comportamento Animal/efeitos dos fármacos , Química Encefálica/efeitos dos fármacos , Córtex Cerebral/patologia , Córtex Cerebral/ultraestrutura , Modelos Animais de Doenças , Progressão da Doença , Relação Dose-Resposta a Droga , Eletroencefalografia/métodos , Epilepsia/patologia , Comportamento Exploratório/efeitos dos fármacos , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Fluidez de Membrana/efeitos dos fármacos , Microscopia Eletrônica de Transmissão/métodos , Carbonilação Proteica/efeitos dos fármacos , Carbonilação Proteica/fisiologia , Proteína Quinase C/metabolismo , Ratos , Ratos Wistar , ATPase Trocadora de Sódio-Potássio/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Gravação de Videoteipe/métodos
3.
J Ethnopharmacol ; 111(1): 56-62, 2007 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-17189676

RESUMO

Bacopa monniera is a perennial herb, and is used as a nerve tonic in äyurveda, a traditional medicinal system in India. Aluminium-induced neurotoxicity is well known and different salts of aluminium have been reported to accelerate oxidative damage to biomolecules like lipids, proteins and nucleic acids. The objective of the present study was to investigate whether Bacopa monniera could potentially inhibit aluminium toxicity in the cerebral cortex. Male Wister rats (8 months old) were administered with AlCl(3) orally at a dose of 50mg/kg/day in drinking water for 1 month. Experimental rats were given AlCl(3) along with Bacopa monniera extract at a dose of 40 mg/kg/day. One group of rats was treated with l-deprenyl at a dose of 1mg/kg/day along with AlCl(3) treatment. We have observed that Bacopa monniera prevented accumulation of lipid and protein damage significantly, which resulted from aluminium intake. Decline in the activity of endogenous antioxidant enzymes associated with aluminium administration was also inhibited by Bacopa monniera extract. The potential of Bacopa monniera to inhibit Al-induced oxidative stress was observed to be similar to that of l-deprenyl, which was taken as standard. The potential of Bacopa monniera extract to prevent aluminium neurotoxicity was reflected at the microscopic level as well, indicative of its neuroprotective effects. These findings strongly implicate that Bacopa monniera has potential to protect brain from oxidative damage resulting from aluminium toxicity.


Assuntos
Antioxidantes/farmacologia , Bacopa , Córtex Cerebral/efeitos dos fármacos , Peroxidação de Lipídeos/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Síndromes Neurotóxicas/prevenção & controle , Estresse Oxidativo/efeitos dos fármacos , Aldeídos/metabolismo , Cloreto de Alumínio , Compostos de Alumínio , Animais , Antioxidantes/uso terapêutico , Córtex Cerebral/metabolismo , Córtex Cerebral/ultraestrutura , Cloretos , Modelos Animais de Doenças , Glutationa/metabolismo , Glutationa Peroxidase/metabolismo , Glutationa Transferase/metabolismo , Índia , Masculino , Ayurveda , Fármacos Neuroprotetores/uso terapêutico , Síndromes Neurotóxicas/etiologia , Síndromes Neurotóxicas/metabolismo , Síndromes Neurotóxicas/patologia , Extratos Vegetais/farmacologia , Carbonilação Proteica/efeitos dos fármacos , Ratos , Ratos Wistar , Selegilina/farmacologia , Superóxido Dismutase/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA